| Literature DB >> 25176038 |
Zainab AlKhatib1, Marcel Lagedroste, Julia Zaschke, Manuel Wagner, André Abts, Iris Fey, Diana Kleinschrodt, Sander H J Smits.
Abstract
The lantibiotic nisin is a small 3.4 kDa antimicrobial peptide, which acts against Gram-positive bacteria in the nmol/L range. Nisin is produced and secreted by several Lactococcus lactis strains to ensure advantages against other bacteria in their habitat. Nisin contains five specific lanthionine rings of which the first two are important for Lipid II binding and the last two are crucial for the pore formation in the membrane. To gain immunity against nisin, the producing strain is expressing an ABC transporter called NisFEG, which expels nisin from the membrane. As a result six to eightfold more nisin is needed to affect the cells. The hydrolysis of ATP by NisFEG is required for this immunity as shown by a mutant, where the ATP hydrolysis is disrupted (NisFH181A EG). Furthermore, NisFEG recognizes the C-terminus of nisin, since deletion of the last six amino acids as well as of the last ring lowered the fold of immunity displayed by NisFEG.Entities:
Keywords: ABC transporter; immunity; lantibiotic; nisin; resistance
Mesh:
Substances:
Year: 2014 PMID: 25176038 PMCID: PMC4234265 DOI: 10.1002/mbo3.205
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Figure 1Nisin variants used in this study. Schematically shown is the wild-type nisin peptide structure as well as the variants CCCCA, CCCAA Nisin1-28 and Nisin1-22. Highlighted in yellow are the dehydrated residues and the lanthionine rings are highlighted with a red line. The lanthionine rings are numbered A–E.
Primers used in this study.
| Name | Sequence (5′–3′) |
|---|---|
| pIL-SV-for | CAGCTTTCTTGTACAAAGTGGTGATGG |
| pIL-SV-rev | GGAGCTGTAATATAAAAACCTTCTTC |
| pUC19Inf-pIL-for | TTATATTACAGCTCCTCTTCCGCTTCCTCGCTCAC |
| pUC19Inf-pILrev | TATTGATCTTGGAGCGAAAGGGCCTCGTGATACGC |
| pIL-SV-P-for | GCTCCAAGATCAATAGAAACATTAAC |
| pIL-SV-P-rev | TGTACAAGAAAGCTGGCGGCCGCCTATTTGAGTGC |
| nisFEGNotI-for | CAAATAGGCGGCCGCATGCAGGTAAAAATTCAAAATCTTTCTAAAACATATAAAG |
| nisFEGSacI-rev | GAATTCGAGCTCCACAAGAAAAAATACTTTATCTAATCTTTTTTTTAG |
| NisF-H181A-for | GACAATCTTGATTTCTAGTGCTCAGTTGCACGAAATAAGTAAAG |
| NisF-H181A-rev | CTTTACTTATTTCGTGCAACTGAGCACTAGAAATCAAGATTGTC |
| CCCCA_for | CAGCAACTTGTCATGCTAGTATTCACGTAA G |
| CCCCA_rev | GCTTACCTGAATACTAGCATGACAAGTTGCTG |
| CCCAA_for | GGAGCTCTGATGGGTTGTAACATGAAA AC |
| CCCAA_rev | GTTTTCATGTTACAACCCATCAGAGCTCC |
| Nisin1-22_for | GCTTACGTGAATTTAACAATGACAAGTTGC |
| Nisin1-22_rev | GCAACTTGTCATTGTTAAATTCACGTAAGC |
Shown are the primers used to create the pIL-SV-NisFEG and pIL-SV-NisFH181AEG expression plasmid, as well as the nisin mutants: CCCCA, CCCAA and the truncations Nisin1-28 and Nisin1-22.
Strains used in this study.
| Strain | Plasmid | Characteristics | Reference |
|---|---|---|---|
| NZ9000 | – | nisRK+ and an empty plasmid | de Ruyter et al. ( |
| NZ9000NisFEG | pILSV-NisFEG | nisFEG | This work |
| NZ9000NisFH181AEG | pILSV-NisFH181AEG | This work | |
| NZ9700 | – | nisABTCIPRKEFG (Wild-type nisin producer) | Kuipers et al. ( |
Figure 2IC50 determination of nisin against different strains. Growth inhibition experiments were performed with nisin using the NZ9000Erm (●), NZ9000NisFEG (♦), NZ9000FH181AEG (open square) and NZ9700 strain (▼). Data was fitted and evaluated according to equation (1). Each experiment was performed at least in triplicates.
IC50 values of nisin and its variants against the NZ9000Erm and NZ9000NisFEG strains.
| NZ9000Erm (nmol/L) | NZ9000NisFEG (nmol/L) | Fold of immunity | |
|---|---|---|---|
| Nisin | 9 ± 0.7 | 59 ± 3.7 | 6.5 |
| CCCCA | 74 ± 1.7 | 237 ± 32 | 3.6 |
| CCCAA | 182 ± 8 | 624 ± 87 | 3.4 |
| Nisin1-28 | 177 ± 15 | 678 ± 78 | 3.8 |
| Nisin1-22 | 224 ± 15 | 578 ± 63 | 2.5 |
Besides the IC50 values, also the fold of immunity against the nisin variants mediated by NisFEG is shown.
Figure 3SYTOx green assay to visualize pore formation mediated by nisin. (A) NZ9000Erm strain (B) NZ9000NisFEG strain (C) NisFH181AEG were grown and incubated with the SYTOX green dye. The fluorescence signal was monitored online using a fluorolog (Horiba III). After a stable baseline was reached nisin was added and pore formation was monitored by measuring the increase in the fluorescence signal. Black curve: buffer control green curve 10 nmol/L nisin; blue curve 30 nmol/L nisin; orange curve 100 nmol/L nisin. The rapid increase in the fluorescence indicated pore formation.
Figure 4Cleavage reaction of prenisin variants analyzed by RP-HPLC: (A) RP-HPLC profile following the cleavage reaction of NisP with the modified CCCCA precursor peptide. The modified precursor CCCCA peptide (red) was digested with NisP and analyzed by RP-HPLC. The digested sample (green) showed two peaks. One at an elution time of 13.5 min corresponding to the leader peptide, which was confirmed by mass spectrometric analysis. The second peak eluted at 22 min, which run similar as the active nisin (blue) which was used as control. (B) SDS-PAGE analysis of the activated nisin variants. Exemplary shown is the activation of the CCCCA variant. Left lane: prenisin form of the CCCCA variants. Right lane: activated nisin variant after NisP treatment and HPLC analysis.
Figure 5IC50 determination of the CCCCA, CCCAA, Nisin1-28 and Nisin1-22 against the (A) NZ9000Erm and (B) NZ9000NisFEG strains. Growth inhibition experiments were performed with the nisin variant using the NZ9000Erm and NZ9000NisFEG. Data was fitted and evaluated according to equation (1). Each experiment was performed at least in triplicates.